Ligand Pharmaceuticals, Inc. (LGND)
285.60
-4.14
(-1.43%)
USD |
NASDAQ |
Sep 04, 16:00
285.75
+0.15
(+0.05%)
After-Hours: 20:00
Ligand Pharmaceuticals Research and Development Expense (Quarterly) : 14.67M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.67M |
| March 31, 2026 | 2.148M |
| December 31, 2025 | 3.511M |
| September 30, 2025 | 21.02M |
| June 30, 2025 | 6.567M |
| March 31, 2025 | 50.08M |
| December 31, 2024 | 4.425M |
| September 30, 2024 | 5.675M |
| June 30, 2024 | 5.354M |
| March 31, 2024 | 5.971M |
| December 31, 2023 | 5.511M |
| September 30, 2023 | 5.601M |
| June 30, 2023 | 7.289M |
| March 31, 2023 | 7.042M |
| December 31, 2022 | 9.229M |
| September 30, 2022 | 9.212M |
| June 30, 2022 | 8.646M |
| March 31, 2022 | 9.19M |
| December 31, 2021 | 8.219M |
| September 30, 2021 | 16.94M |
| June 30, 2021 | 16.28M |
| March 31, 2021 | 17.35M |
| December 31, 2020 | 21.77M |
| September 30, 2020 | 12.85M |
| June 30, 2020 | 12.73M |
| Date | Value |
|---|---|
| March 31, 2020 | 8.933M |
| December 31, 2019 | 2.932M |
| September 30, 2019 | 13.74M |
| June 30, 2019 | 12.21M |
| March 31, 2019 | 11.29M |
| December 31, 2018 | 8.84M |
| September 30, 2018 | 5.483M |
| June 30, 2018 | 6.135M |
| March 31, 2018 | 7.407M |
| December 31, 2017 | 8.633M |
| September 30, 2017 | 4.759M |
| June 30, 2017 | 4.822M |
| March 31, 2017 | 8.673M |
| December 31, 2016 | 6.408M |
| September 30, 2016 | 5.898M |
| June 30, 2016 | 4.914M |
| March 31, 2016 | 4.004M |
| December 31, 2015 | 2.87M |
| September 30, 2015 | 1.945M |
| June 30, 2015 | 4.01M |
| March 31, 2015 | 3.962M |
| December 31, 2014 | 3.199M |
| September 30, 2014 | 3.021M |
| June 30, 2014 | 2.689M |
| March 31, 2014 | 3.131M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Zevra Therapeutics, Inc. | 4.486M |
| Liquidia Corp. | 16.88M |